President Trump signed an executive order on April 18, 2026, aimed at expanding federal research into psychedelic drugs, including ibogaine. Officials said the move is intended to accelerate studies into new treatments for mental health conditions, particularly among veterans and patients who have not responded to existing therapies.
The announcement took place at the White House with Joe Rogan in attendance, alongside Robert F. Kennedy Jr. and other supporters. Reports around the event noted that Rogan has been a vocal advocate for ibogaine and played a role in bringing attention to the issue within Trump’s circle.
The order focuses on easing some of the regulatory barriers that have slowed research into substances that remain restricted under federal law. Ibogaine, a naturally derived psychedelic, has been studied for its potential to address addiction and trauma-related conditions, though it continues to raise safety concerns among medical experts.
Officials described the directive as part of a broader effort to explore alternative treatments while maintaining oversight through controlled studies and clinical evaluation.
